Idioma:

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers

Kooshkaki, Omid ; Derakhshani, Afshin ; Safarpour, Hossein ; Najafi, Souzan ; Vahedi, Parviz ; Brunetti, Oronzo ; Torabi, Mitra ; Lotfinejad, Parisa ; Paradiso, Angelo Virgilio ; Racanelli, Vito ; Silvestris, Nicola ; Baradaran, Behzad

International journal of molecular sciences, 2020-07, Vol.21 (14), p.5034 [Periódico revisado por pares]

Switzerland: MDPI

Texto completo disponível

Citações Citado por

Enviar para

Título:
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers
Autor: Kooshkaki, Omid ; Derakhshani, Afshin ; Safarpour, Hossein ; Najafi, Souzan ; Vahedi, Parviz ; Brunetti, Oronzo ; Torabi, Mitra ; Lotfinejad, Parisa ; Paradiso, Angelo Virgilio ; Racanelli, Vito ; Silvestris, Nicola ; Baradaran, Behzad
Assuntos: Animals ; Antineoplastic Agents, Immunological - adverse effects ; Antineoplastic Agents, Immunological - therapeutic use ; Female ; Genital Neoplasms, Female - drug therapy ; Genital Neoplasms, Female - immunology ; Genital Neoplasms, Female - pathology ; Genital Neoplasms, Female - therapy ; Genitalia, Female - drug effects ; Genitalia, Female - immunology ; Genitalia, Female - pathology ; gynecologic cancers ; Humans ; immune checkpoint inhibitors ; Immune Checkpoint Inhibitors - adverse effects ; Immune Checkpoint Inhibitors - therapeutic use ; PD-1 inhibitors ; PD-L1 inhibitors ; Review
É parte de: International journal of molecular sciences, 2020-07, Vol.21 (14), p.5034
Descrição: Gynecologic cancers account for approximately 11% of the newly diagnosed cancers in women in the United States and for 18% globally. The presence of tumor-infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune checkpoint inhibitors (ICIs), including anti programmed cell death protein-1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), and anticytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), which have been approved for treating different types of malignancies. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host-tumor interaction. There are several the US food and drug administration (FDA)-approved ICIs targeting PD-1, including pembrolizumab and nivolumab, as well as those targeting PD-L1, including avelumab, atezolizumab, and durvalumab for melanoma, renal cell cancer, colorectal cancer, head and neck cancer, cervix cancer, urothelial cancer, and lung cancer. Current pre-clinical and clinical studies assessing PD-1/PD-L1 inhibitors in several gynecologic cancers have reported significant antitumor activity. In this review, we investigate pre-clinical and clinical studies that describe the safety and efficacy of anti-PD-1/PD-L1 antibodies, with a particular focus on ongoing clinical trials, analyzing the oncological outcome and adverse effects of ICIs in gynecologic cancers.
Editor: Switzerland: MDPI
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers

Kooshkaki, Omid ; Derakhshani, Afshin ; Safarpour, Hossein ; Najafi, Souzan ; Vahedi, Parviz ; Brunetti, Oronzo ; Torabi, Mitra ; Lotfinejad, Parisa ; Paradiso, Angelo Virgilio ; Racanelli, Vito ; Silvestris, Nicola ; Baradaran, Behzad

Switzerland: MDPI

Buscando em bases de dados remotas. Favor aguardar.